Next-Gen Akkermansia muciniphila AH39
Exhibitor Products
Information
Akkermansia muciniphila AH39, recognized as a promising next-generation probiotic, plays a key role in maintaining gut barrier integrity and metabolic balance.
Our proprietary strain AH39 has been clinically validated in an 8-week randomized, double-blind, controlled trial in overweight and obese adults.
sGRAS Status – Globally recognized safety for food and supplement applications
With proven clinical efficacy and strong safety backing, AH39 opens new opportunities for weight management, liver health, and next-generation gut health solutions.
